Croda Health Care Exhibiting at CPhI
11 September 2006
Croda Health Care have announced they are exhibiting at CPhI, the world's largest pharmaceutical industry gathering, and can be found on stand 5H80 (Hall 5a). By visiting the Croda stand pharmaceutical formulators can find out how they can reduce cellular irritation and improve API stability in a variety of delivery systems.
For topical and transdermal systems, Croda has shown that chromatographically purifying polysorbates removes oxidative and polar impurities and so reduces skin irritation compared with standard monographed grades. Similar purification of PEG-400 significantly increased the stability of solubilised drug actives. This new Super Refined PEG finds application in any oral, topical and parenteral formulations where PEG-400 is used as an API solvent. Croda's complete ranges of drug delivery excipients and lipid actives for pharmaceutical and dermatological applications will also be on show.
New launches for CPhI 2006 include:
- The first in Croda's "Condition-specific dermatology" series designed to help customers develop clinically effective formulations with outstanding aesthetics
- Super Refined Polysorbate 80, setting a new standard for excipient purity, delivering enhanced API stability, better analytical clarity and reduced cellular irritation
- New data on Super Refined PEGs demonstrating that they can significantly increase the stability of solubilised drug actives
Showcase Seminar
For more details don't miss the showcase seminar by Dr Nigel Langley, Technical Director of Croda Health Care's US operations, entitled:
"Does the purity of PEG 400 affect API stability and the degree of gelatin cross-linking?" taking place Thurs, 5 October 2006, Hall 6 (6H78), 12.55 - 13.15pm.
